The European Medicines Agency has given orphan drug designation to YH35995, Yuhan Corporation‘s investigational oral therapy for Gaucher disease, following a similar decision from the U.S. Food and Drug Administration in April. Orphan drug designation is granted to medicines for rare diseases, defined in the European Union as…
News
Levels of the Gaucher disease biomarker glucosylsphingosine (lyso-Gb1) can have different trajectories in people who aren’t actively receiving treatment, a study found. While most untreated patients showed relatively little change in lyso-Gb1 over time, more than one-third experienced increases in the biomarker, which weren’t always associated with immediate disease…
Adults with Gaucher disease type 1 may develop subtle signs of heart dysfunction long before they experience symptoms or show abnormalities on standard heart tests, according to a small new study from Turkey. The researchers found that an advanced heart imaging scan — an ultrasound technique called speckle-tracking echocardiography,…
People with Gaucher disease type 1 are known to be at increased risk of Parkinson’s disease, but data from a new study show that fewer than 15% of those with this disease type — marked by an absence of neurological symptoms — will develop Parkinson’s in their lifetime.
The U.S. Food and Drug Administration (FDA) has granted priority review to an application for venglustat, an experimental substrate reduction therapy (SRT) that Sanofi is developing for Gaucher disease type 3. The FDA grants priority review to applications for therapies that may offer significant improvements for serious…
Extending genetic testing beyond the person initially diagnosed with Gaucher disease can uncover additional affected relatives who might otherwise go undetected, according to a new study. When researchers tested family members of Gaucher patients, some relatives, including siblings, children, grandparents, aunts, and uncles, were either genetic carriers or undiagnosed…
One-time treatment with avigbagene parvec, a gene therapy being developed by Spur Therapeutics, may improve bone health in adults with Gaucher disease. That’s according to data from a now-completed Phase 1/2 clinical trial, GALILEO-1 (NCT05324943), and its ongoing long-term extension study, GALILEO-2 (NCT06545136), showing that…
Colchicine, an approved anti-inflammatory medication for treating gout, significantly reduced fat accumulation and signs of cellular damage in a cell model of Gaucher disease, according to a new study. The lab findings suggest that the oral treatment — which was identified for potential use in Gaucher with the aid…
VPRIV (velaglucerase alfa) may help improve bone marrow health in adults with Gaucher disease type 1, but its benefit for bone strength appears to be modest and may vary from patient to patient, a small Phase 4 clinical study found. The study, “Improvement of Bone Mineral Density…
Long-term treatment with Cerezyme (imiglucerase), or its discontinued predecessor Ceredase (alglucerase), led to rapid and progressive improvements in blood counts, growth, and bone health, as well as reductions in liver and spleen size, in children with Gaucher disease (GD) — including among youngsters with a more severe disease…
Recent Posts
- The joy of running has become a metaphor for life with a rare disease
- FDA approves first drug, Infilbray, for neurological problems in Gaucher
- Small study highlights delays in diagnosis in Gaucher disease patients
- Finding my own ‘happily ever after’ in a life with Gaucher disease
- While I was worried about the effects of Gaucher, life happened anyway